SoniVie Receives FDA Breakthrough Device Designation for the TIVUS System for Renal Artery Denervation  - SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension - TEL AVIV, Israel, Dec. 09, 2020 (GLOBE...

SoniVie Receives IDE Approval for its Pivotal Study for the TIVUS System to Treat Patients with Pulmonary Arterial Hypertension (PAH) - International study designed to build on positive 12-month data from TROPHY1 demonstrating improvement in multiple clinical endpoints and no serious procedure-related adverse events- TEL...